A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Bora Pharmaceuticals Co., Ltd. engages in contract development, manufacture, and sale of pharmaceuticals in Europe, the United States, Taiwan, and internationally. The company operates through Sales, CDMO, and Other segments. It manufactures and sells generic, brand, and over the counter (OTC) drugs. The company also offers contract development and manufacturing services and technical services for the development of pharmaceutical products. In addition, it provides Western pharmaceuticals, including central nervous system medications, antibiotics, and gastrointestinal medications; and nutritional and vitamin supplements, physical recovery, and health care products. The company sells its products directly to clinics, pharmacies, pharmacy chains, and drug stores, as well as through distributors to medical centers, corporate and public hospitals, and regional and district hospitals. Bora Pharmaceuticals Co., Ltd. was incorporated in 2007 and is based in Taipei City, Taiwan.
Financial Summary
| Share Statistics | BORAY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,508.6 | $579.1 | 50% |
|
| Shares Out (Mil) | 4.1 | 43.0 | 12% |
|
| Institutional Ownership | 60.3% | 84.3% | 39% |
|
| Float (Mil) | 74.3 | 46.8 | 56% |
|
| Beta | 0.43 | 0.62 | 24% |
|
| Avg Daily Volume (000s) | 3 | 285 | 11% |
|
| Price Change (52-week) |
na | 63.8% | na |
|
| Growth | BORAY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 56.7% | 6.7% | 97% |
|
| Net Income (5yr) | 35.7% | (1.4%) | 88% |
|
| EPS (5yr) | 23.1% | 14.9% | 72 |
|
| Dividends (5yr) | 57.1% | 0.0% | 64% |
|
| Cash Flow (5yr) | (39.0%) | (14.9%) | 12% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | BORAY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $580 | $272 | 43% |
|
| Net Income (TTM) (Mil) | $50 | ($11) | 55% |
|
| EPS (TTM) | $0.400 | ($0.500) | 51% |
|
| Operating Cash Flow (TTM) (Mil) | $118 | ($6) | 54% |
|
| Net Cash Flow (TTM) (Mil) | ($11) | $4 | 30% |
|
| Long-Term Debt (Q1) (Mil) | $406 | $7 | 57% |
|
| Enterprise Value (Q1) (Mil) | $2,105 | $522 | 50% |
|
| Valuation | BORAY | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.73 | na |
|
| P/E | na | 20.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | BORAY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 40.0% | 65.9% | 50% |
|
| Net Margin | 8.7% | 0.7% | 59% |
|
| ROA | 3.6% | (24.6%) | 65% |
|
| ROE | 11.8% | (19.7%) | 63% |
|
| Liabilities to Assets | 63.3% | 35.5% | 58% |
|
| F-Score | na | 3 | na |
|
Bora Pharmaceuticals Co., Ltd. did not pass any screens on 7/31/2026.
